/BIVI

BIVI Stock - BioVie Inc.

Q: What is the analyst price target for BIVI?

Analyst price target information is not currently available for BIVI.

Q: What is BIVI's market cap?

Market capitalization information is not currently available for BIVI.

Healthcare|Biotechnology|NASDAQ

$1.41-2.76%

$0.04 (-2.76%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.55

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BIVI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.53

52W High$25.76

52W Low$1.25

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-229,377	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-18,066,200	$-32,179,585	$-45,080,448	$-27,252,977	$-138,054,000
Net Income	$-17,542,120	$-32,120,533	$-50,255,815	$-26,084,468	$-130,249,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-12.12	$-73.05	$-154.70	$-106.00	$-1482.30

Company Overview

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish0 Neutral/Bearish

Price Targets

Average Target

↑ 396.5% Upside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 22nd 2022	Cantor Fitzgerald	Initiation	Overweight	$7

Earnings History & Surprises

BIVI

Beat Rate

47%

Last 17 quarters

Avg Surprise

-4112.2%

EPS vs Estimate

Beats / Misses

8/9

Last 12 quarters

Latest EPS

$-0.98

Q4 2025

EPS Surprise History

Q1 24

+31.3%

$-22.00vs$-32.00

Q2 24

-5960.6%

$-20.00vs$-0.33

Q3 24

-340.0%

$-66.00vs$-15.00

Q4 24

+56.3%

$-7.00vs$-16.00

Q1 25

+71.3%

$-4.60vs$-16.00

Q2 25

+53.1%

$-1.50vs$-3.20

Q3 25

+94.6%

$-0.24vs$-4.40

Q4 25

-24.1%

$-0.98vs$-0.79

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Feb 10, 2026	$-0.81	—	—	—
Q4 2025	Nov 10, 2025	$-0.79	$-0.98	-24.1%	✗ MISS
Q3 2025	Aug 15, 2025	$-4.40	$-0.24	+94.6%	✓ BEAT
Q2 2025	May 12, 2025	$-3.20	$-1.50	+53.1%	✓ BEAT
Q1 2025	Feb 11, 2025	$-16.00	$-4.60	+71.3%	✓ BEAT
Q4 2024	Nov 13, 2024	$-16.00	$-7.00	+56.3%	✓ BEAT
Q3 2024	Sep 30, 2024	$-15.00	$-66.00	-340.0%	✗ MISS
Q2 2024	May 14, 2024	$-0.33	$-20.00	-5960.6%	✗ MISS
Q1 2024	Feb 12, 2024	$-32.00	$-22.00	+31.3%	✓ BEAT
Q4 2023	Nov 8, 2023	$-0.31	$-29.00	-9254.8%	✗ MISS
Q3 2023	Aug 16, 2023	$-37.00	$-23.00	+37.8%	✓ BEAT
Q2 2023	May 12, 2023	$-0.35	$-43.00	-12185.7%	✗ MISS
Q1 2023	Feb 10, 2023	$-0.25	$-50.00	-19900.0%	✗ MISS
Q4 2022	Nov 4, 2022	$-0.28	$-38.00	-13471.4%	✗ MISS
Q3 2022	Sep 27, 2022	$-0.37	$-33.00	-8818.9%	✗ MISS
Q2 2022	May 11, 2022	$-0.42	$-0.28	+33.3%	✓ BEAT
Q1 2022	Feb 8, 2022	$-0.31	$-0.28	+9.7%	✓ BEAT
Q4 2021	Nov 10, 2021	—	$-23.36	—	—
Q3 2021	Aug 30, 2021	$-2.32	$-10.18	-338.8%	✗ MISS